CROI 2015 Program and Abstracts

Oral Sessions

161 The Impact of Antiretroviral Therapy on Adult Life Expectancy in Sub- Saharan Africa Georges Reniers 8 ; Jeffrey Eaton 1 ; Jessica Nakiyingi-Miiro 2 ; Amelia C. Crampin 4 ; Chodziwadziwa Kabudula 5 ; Kobus Herbst 3 ; Mark Urassa 6 ; Amek Nyaguara 7 ; Emma Slaymaker 8 On behalf of the ALPHA Network 1 Imperial College London, London, United Kingdom; 2 MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda; 3 Africa Centre for Health and Population Studies, Mtubatuba, South Africa; 4 Karonga Prevention Study, Chilumba, Malawi; 5 University of the Witwatersrand, Johannesburg, South Africa; 6 National Institute for Medical Research, Mwanza, United Republic of Tanzania; 7 Kenya Medical Research Institute-Centers for Disease Control, Kisumu, Kenya; 8 London School of Hygiene and Tropical Medicine, London, United Kingdom 10:00 am– 12:15 pm Immune Mechanisms: The Road to Protection Moderators Katharine J. Bar , University of Pennsylvania, Philadelphia, PA, US Bruce Walker , Ragon Institute of MIT, MGH and Harvard, Cambridge, MA, US 162 Passively Acquired ADCC Activity in HIV-Infected Infants Correlates With Survival Caitlin Milligan 1 ; Barbra A. Richardson 1 ; Grace John-Stewart 2 ; RuthW. Nduati 3 ; Julie M. Overbaugh 1 1 Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US; 2 University of Washington, Seattle, WA, US; 3 University of Nairobi, Nairobi, Kenya 163 AAV-Expressed eCD4-Ig Protects Rhesus Macaques FromMultiple SHIV-AD8 Challenges Michael Farzan The Scripps Research Institute, Jupiter, FL, US 164LB HIV Neutralizing Antibodies Induced by Native-Like Envelope Trimers Rogier Sanders TheWCMC/Scripps/AMC HIVRAD team Academic Medical Center University of Amsterdam, Amsterdam, Netherlands 165 Efficacy Loss of BnAbs During HIV-1 Cell-Cell Spread Is Strain- and Epitope-Dependent Lucia Reh ; Carsten Magnus; Merle Schanz; JacquelineWeber;Therese Uhr; Peter Rusert; AlexandraTrkola University of Zurich, Zurich, Switzerland 166 Peripheral T Follicular Helper Cells With Universal Helper Activity in HIV Infection Bruce Schultz; Alexander Oster; Franco Pissani; Jeffrey E.Teigler; Michael A. Eller; Merlin L. Robb; Jerome H. Kim; Nelson L. Michael; Diane Bolton; Hendrik Streeck US Military HIV Research Program, Silver Spring, MD, US 167 Redirected Killing of HIV-Infected T Cells by Germinal Center CD8 T Cells Constantinos Petrovas 1 ; Sara Ferrando-Martinez 1 ; Michael Gerner 2 ; Amarendra Pegu 1 ; Perla Del Río-Estrada 3 ; Kristin Boswell 1 ; Manuel Leal 4 ; Gustavo Reyes-Teran 3 ; Ronald Germain 2 ; Richard A. Koup 1 1 Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, US; 2 NIAID-NIH, Bethesda, MD, US; 3 Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; 4 Instituto de Biomedicina de Sevilla, Sevilla, Spain 168 IL-21 Reduces Inflammation and Virus Persistence in ART-Treated SIV- Infected Macaques Luca Micci 1 ; Emily Ryan 1 ; Colleen McGary 1 ; Sara Paganini 1 ; Guido Silvestri 1 ; Mike Piatak 2 ; Jeffrey Lifson 2 ; FrancoisVillinger 1 ; Jason M. Brenchley 3 ; Mirko Paiardini 1 1 Yerkes National Primate Research Center, Emory University, Atlanta, GA, US; 2 Leidos Biomedical Research, Inc, Frederick, MD, US; 3 National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US 169 Discovery of CD8 + T Cell Epitopes Encoded by the HIV 5’Leader Sequence Edward Kreider 1 ; Katja J. Pfafferott 2 ;Thomas Partridge 2 ; Hui Li 1 ; RanjitWarrier 1 ; Benedikt M. Kessler 2 ; Andrew J. McMichael 2 ; Persephone Borrow 2 ; Beatrice H. Hahn 1 ; George M. Shaw 1 1 University of Pennsylvania, Philadelphia, PA, US; 2 University of Oxford, Headington, United Kingdom Session O-14 Oral Abstracts Room 613

170LB Neutralizing Antibodies Differ Between HIV-1 – Infected RV144 Vaccinees and Placebos Shelly J. Krebs 1 ; Morgane Rolland 1 ; SodsaiTovanabutra 1 ; Ivelin Georgiev 2 ; Agnes-Laurence Chenine 1 ;Victoria R. Polonis 1 ; Supachai Rerks-Ngarm 3 ; Peter D. Kwong 2 ; Nelson L. Michael 1 ; Jerome H. Kim 1 On behalf of the RV152 Study Group 1 US Military HIV Research Program, Silver Spring, MD, US; 2 Vaccine Research Center, NIAID, NIH, Bethesda, MD, US; 3 Ministry of Public Health, Bangkok, Thailand 1:30 pm– 2:30 pm Identifying Recent Infections: Issues of False Recency Themed Discussion Leader Michael Busch , Blood Systems Research Institute, San Francisco, CA, US 612 A Generalized Entropy Measure of Viral Diversity for Identifying Recent HIV-1 Infections JuliaW. Wu ; Oscar Patterson-Lomba; Marcello Pagano Harvard School of Public Health, Boston, MA, US 626 Viral Load is Critical in Limiting False-Recent Results FromHIV Incidence Assays Reshma Kassanjee 1 ; Shelley Facente 2 ; Sheila Keating 3 ; Elaine McKinney 4 ; Kara Marson 2 ; Christopher D. Pilcher 2 ; Michael Busch 3 ; Gary Murphy 4 ; Alex Welte 1 On behalf of the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA) 1 South African DST/NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), University of Stellenbosch, Stellenbosch, South Africa; 2 University of California San Francisco, San Francisco, CA, US; 3 Blood Systems Research Institute, San Francisco, CA, US; 4 Public Health England, London, United Kingdom 625 False Recent Rates for Two Recent Infection Testing Algorithms, South Nyanza, Kenya Clement Zeh 1 ; David Maman 4 ; Harrison Omondi 2 ; Alex Morwabe 2 ; Collins Odhiambo 2 ; Beatrice Kirubi 4 ; Irene Mukui 3 ; MartinusW. Borgdorff 1 ; Jean-François Etard 4 ; Andrea A. Kim 1 1 US Centers for Disease Control and Prevention, Kisumu, Kenya; 2 Kenya Medical Research Institute, Kisumu, Kenya; 3 National AIDS and STI Control and Prevention, Nairobi, Kenya; 4 Médecins Sans Frontières, Paris, France 622 The Effect of HIV-1 Subtype A, C and D on Cross-Sectional Incidence Assay Performance Andrew F. Longosz 2 ; Mary Grabowski 2 ; Charles S. Morrison 3 ; Ronald H. Gray 2 ; Connie Celum 4 ; Quarraisha Abdool Karim 5 ; Hilmarie Brand 6 ;Thomas C. Quinn 1 ; Susan H. Eshleman 2 ; Oliver B. Laeyendecker 1 1 National Institute of Allergy and Infectious Diseases, Baltimore, MD, US; 2 Johns Hopkins University, Baltimore, MD, US; 3 FHI 360, Durham, NC, US; 4 University of Washington, Seattle, WA, US; 5 CAPRISA, University of KwaZulu-Natal, Congella, South Africa; 6 SACEMA, Stellenbosch University, Stellenbosch, South Africa 1:30 pm– 2:30 pm Next-Generation HCV Therapeutics: From Clinical Trials to the Clinic Themed Discussion Leader Debika Bhattacharya , University of California Los Angeles CARE Center, Los Angeles, CA, US 646 German Cohort on Sofosbuvir-Based Therapy for HIV/HCV and HCV Infection (GECOSO) Stefan Christensen 2 ; Ingiliz Patrick 3 ; Dietrich Hueppe 7 ;Thomas Lutz 4 ; Karl Georg Simon 6 ; Knud Schewe 5 ; Heiner Busch 2 ; Axel Baumgarten 3 ; Guenther Schmutz 1 ; Stefan Mauss 1 1 Center for HIV and Hepatogastroenterology, Duesseldorf, Germany; 2 CIM Infectious Diseases, Muenster, Germany; 3 Medizinisches Infektiologie Zentrum Berlin, Berlin, Germany; 4 Infektiologikum, Frankfurt, Germany; 5 Infektionsmedizinisches Centrum Hamburg, Hamburg, Germany; 6 Practice for Gastroenterology Leverkusen, Leverkusen, Germany; 7 Practice for Gastroenterology Herne, Herne, Germany Session TD-M Themed Discussion Room 615 Session TD-N Themed Discussion Room 6AB

Thursday, February 26, 2015 • Oral Sessions

18

CROI 2015